JO3691B1 - سترويدات وتركيبات نشطة عصبياً، واستخداماتها - Google Patents

سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Info

Publication number
JO3691B1
JO3691B1 JOP/2015/0132A JOP20150132A JO3691B1 JO 3691 B1 JO3691 B1 JO 3691B1 JO P20150132 A JOP20150132 A JO P20150132A JO 3691 B1 JO3691 B1 JO 3691B1
Authority
JO
Jordan
Prior art keywords
disorders
present application
treatment
range
compositions
Prior art date
Application number
JOP/2015/0132A
Other languages
English (en)
Inventor
G Salituro Francesco
Thomas Beresis Richard
L Harrison Boyd
Jean Robichaud Albert
Martinez Botella Gabriel
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Application granted granted Critical
Publication of JO3691B1 publication Critical patent/JO3691B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم في الطلب الحالي 19-نور C3, 3-سترويدات ليس بها استبدال لها الصيغة (I): (I) وأملاح منها مقبولة صيدلانياً; حيث R1، R2، R3، وR4 تكون وفقاً لما تم تعريفه في الطلب الحالي، وA تكون نظام حلقة أريل غير متجانسة يشتمل على 3 أو 4 ذرات نيتروجين وفقاً لما تم تعريفه في الطلب الحالي. من المتوقع أن تكون مثل هذه المركبات مفيدة للوقاية من وعلاج مجموعة من الحالات المتعلقة بـ CNS، على سبيل المثال، علاج اضطرابات النمو، اضطرابات المزاج، اضطرابات نطاق انفصام الشخصية، اضطرابات تشنج، اضطرابات الذاكرة و/أو الإدراك، اضطرابات الحركة، اضطرابات الشخصية، اضطراب أنواع التوحد، ألم، إصابة مخ رضحية، أمراض أوعية دموية، اضطرابات إدمان المخدرات و/ أو متلازمات الانسحاب، وطنين الأذن.
JOP/2015/0132A 2014-05-29 2015-05-31 سترويدات وتركيبات نشطة عصبياً، واستخداماتها JO3691B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014078820 2014-05-29
PCT/CN2015/080216 WO2015180679A1 (en) 2014-05-29 2015-05-29 Neuroactive steroids, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
JO3691B1 true JO3691B1 (ar) 2020-08-27

Family

ID=54698130

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0132A JO3691B1 (ar) 2014-05-29 2015-05-31 سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Country Status (27)

Country Link
US (5) US20180179247A1 (ar)
EP (3) EP3149018B1 (ar)
JP (4) JP6652934B2 (ar)
KR (3) KR102664412B1 (ar)
CN (3) CN114369135A (ar)
AR (2) AR100691A1 (ar)
AU (5) AU2015266447A1 (ar)
CA (2) CA2949720C (ar)
CY (1) CY1124109T1 (ar)
DK (2) DK3705488T3 (ar)
ES (2) ES2927007T3 (ar)
HR (2) HRP20201126T1 (ar)
HU (2) HUE050028T2 (ar)
IL (3) IL248948B (ar)
JO (1) JO3691B1 (ar)
LT (2) LT3705488T (ar)
MX (5) MX382131B (ar)
PH (2) PH12021550762A1 (ar)
PL (2) PL3705488T3 (ar)
PT (2) PT3149018T (ar)
RS (2) RS60529B1 (ar)
RU (2) RU2019126637A (ar)
SG (2) SG10201803812TA (ar)
SI (2) SI3149018T1 (ar)
SM (2) SMT202000406T1 (ar)
TW (3) TW202426001A (ar)
WO (1) WO2015180679A1 (ar)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
HRP20190232T1 (hr) 2013-04-17 2019-03-22 Sage Therapeutics, Inc. 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
HRP20200995T1 (hr) 2013-04-17 2020-11-27 Sage Therapeutics, Inc. 19-nor neuroaktivni steroidi za metode liječenja
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
SMT202100229T1 (it) 2013-07-19 2021-05-07 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
SMT202100048T1 (it) 2013-08-23 2021-03-15 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
HUE050028T2 (hu) * 2014-05-29 2021-12-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
AU2015331749A1 (en) 2014-10-16 2017-05-04 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
JP6742308B2 (ja) 2014-10-16 2020-08-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
ES2793237T3 (es) 2014-11-27 2020-11-13 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3362042A1 (en) 2015-10-16 2018-08-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
SG11201807785VA (en) * 2016-03-08 2018-10-30 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
CN109689673B (zh) * 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN115974954A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
MA51315A (fr) * 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter des troubles du snc
CN114656514B (zh) * 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
CA3124703C (en) * 2019-01-14 2023-10-17 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
AU2020302748A1 (en) 2019-06-27 2022-01-06 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
WO2021023213A1 (zh) 2019-08-07 2021-02-11 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
JP2024507638A (ja) * 2021-01-28 2024-02-21 セージ セラピューティクス， インコーポレイテッド 性機能障害処置のための神経刺激性ステロイドの使用
CA3226489A1 (en) * 2021-07-28 2023-02-02 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
US20250170147A1 (en) 2022-02-28 2025-05-29 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
WO2024189061A1 (en) 2023-03-14 2024-09-19 Curia Spain, S.A.U. Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids
EP4711377A1 (en) * 2023-05-11 2026-03-18 Shujing Biopharma Co., Ltd Steroid compound, preparation method therefor, and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634717A1 (de) * 1986-10-11 1988-04-14 Dynamit Nobel Ag Verfahren zur herstellung von 5-methyltetrazol
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
FR2679263B1 (fr) 1991-07-15 1994-01-14 Staubli Ets Perfectionnements aux ratieres a double leve du type hattersley pour machines a tisser.
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
NZ282939A (en) * 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
CN1187367C (zh) * 1999-04-29 2005-02-02 欧洲凯尔特股份有限公司 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇
AU2003301368A1 (en) * 2002-10-15 2004-05-04 Medtronic Inc. Scoring of sensed neurological signals for use with a medical device system
US7729773B2 (en) * 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
ES2738526T3 (es) * 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
HUE050028T2 (hu) * 2014-05-29 2021-12-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
JP6742308B2 (ja) * 2014-10-16 2020-08-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法

Also Published As

Publication number Publication date
ES2805598T3 (es) 2021-02-12
AU2021204410B2 (en) 2023-09-21
TW201625661A (zh) 2016-07-16
MX394493B (es) 2025-03-24
HUE050028T2 (hu) 2021-12-28
IL292461B1 (en) 2023-11-01
JP2017516793A (ja) 2017-06-22
BR112016027508A2 (pt) 2018-06-26
PT3149018T (pt) 2020-07-21
IL304033A (en) 2023-08-01
EP3705488B1 (en) 2022-08-03
CY1124109T1 (el) 2022-03-24
KR102494061B1 (ko) 2023-01-31
CA2949720A1 (en) 2015-12-03
IL292461B2 (en) 2024-03-01
AU2021204410A1 (en) 2021-07-22
EP3149018B1 (en) 2020-04-29
CA3279948A1 (en) 2025-10-31
DK3705488T3 (da) 2022-10-03
CN114369135A (zh) 2022-04-19
NZ764941A (en) 2023-11-24
SI3705488T1 (sl) 2022-10-28
WO2015180679A1 (en) 2015-12-03
US20240076310A1 (en) 2024-03-07
SG11201609813XA (en) 2016-12-29
US20200165291A1 (en) 2020-05-28
NZ764921A (en) 2023-11-24
RS63554B1 (sr) 2022-09-30
AR121661A2 (es) 2022-06-29
TW202426001A (zh) 2024-07-01
LT3705488T (lt) 2022-09-26
US20210061849A1 (en) 2021-03-04
MX2021005106A (es) 2021-06-15
MX382131B (es) 2025-03-13
JP2023123878A (ja) 2023-09-05
KR20170003706A (ko) 2017-01-09
CA2949720C (en) 2025-11-18
AU2026201227A1 (en) 2026-03-12
JP2020073577A (ja) 2020-05-14
EP3149018A4 (en) 2017-12-06
RU2699359C2 (ru) 2019-09-05
TW202231652A (zh) 2022-08-16
AU2015266447A1 (en) 2016-12-01
PL3705488T3 (pl) 2022-12-05
PT3705488T (pt) 2022-09-30
RU2016151727A3 (ar) 2018-12-03
HRP20221294T1 (hr) 2023-03-03
TWI839649B (zh) 2024-04-21
US20210061850A1 (en) 2021-03-04
SG10201803812TA (en) 2018-06-28
JP6652934B2 (ja) 2020-02-26
LT3149018T (lt) 2020-08-10
EP3705488A1 (en) 2020-09-09
AR100691A1 (es) 2016-10-26
AU2019279910B2 (en) 2021-07-22
HRP20201126T1 (hr) 2020-12-11
PL3149018T3 (pl) 2021-01-25
KR20230021165A (ko) 2023-02-13
JP7386204B2 (ja) 2023-11-24
MX2016015532A (es) 2017-02-27
EP3149018A1 (en) 2017-04-05
RS60529B1 (sr) 2020-08-31
IL248948B (en) 2022-09-01
JP6892936B2 (ja) 2021-06-23
AU2023285755B2 (en) 2026-03-12
ES2927007T3 (es) 2022-10-31
IL248948A0 (en) 2017-01-31
PH12016502342A1 (en) 2017-02-13
RU2016151727A (ru) 2018-07-02
IL292461A (en) 2022-06-01
EP4144746A1 (en) 2023-03-08
JP2021130696A (ja) 2021-09-09
DK3149018T3 (da) 2020-07-20
MX2021005099A (es) 2021-06-15
SI3149018T1 (sl) 2020-10-30
KR20240066304A (ko) 2024-05-14
SMT202200416T1 (it) 2022-11-18
AU2019279910A1 (en) 2020-01-16
CN114133423A (zh) 2022-03-04
HUE059829T2 (hu) 2022-12-28
RU2019126637A (ru) 2019-10-03
US20180179247A1 (en) 2018-06-28
MX2023004352A (es) 2023-05-08
SMT202000406T1 (it) 2020-09-10
KR102664412B1 (ko) 2024-05-21
NZ726260A (en) 2023-11-24
PH12021550762A1 (en) 2023-07-17
AU2023285755A1 (en) 2024-01-18
CN106661078A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
JO3691B1 (ar) سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CY1124175T1 (el) Νευροδραστικα στεροειδη 19-nor για μεθοδους θεραπευτικης αντιμετωπισης
MX395023B (es) Esteroides c21-n-pirazolilo 19-nor c3,3-disustituidos y metodos de uso de los mismos.
AR108012A1 (es) Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
MX373274B (es) Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer.
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
JO3146B1 (ar) مشتقات غير متجانسة الحلقية و استخدامها في علاج الاضطرابات العصبية
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201690790A1 (ru) Серосодержащее бициклическое соединение
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
EA201692264A1 (ru) Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201890769A1 (ru) Производные 2,3,4,5-тетрагидропиридин-6-амина
BR112018000925A2 (pt) composto heterocíclico contendo nitrogênio
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions